

Manuel Crespo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1924193/publications.pdf>

Version: 2024-02-01

58
papers

1,601
citations

331670

21
h-index

315739

38
g-index

59
all docs

59
docs citations

59
times ranked

2835
citing authors

#	ARTICLE	IF	CITATIONS
1	Massive Release of CD9+ Microvesicles in Human Immunodeficiency Virus Infection, Regardless of Virologic Control. <i>Journal of Infectious Diseases</i> , 2022, 225, 1040-1049.	4.0	13
2	The benefits and safety of oral sequential antibiotic therapy in non-complicated and complicated <i>Staphylococcus aureus</i> bacteremia. <i>International Journal of Infectious Diseases</i> , 2021, 102, 554-560.	3.3	11
3	Elevated Anti-SARS-CoV-2 Antibodies and IL-6, IL-8, MIP-1 β , Early Predictors of Severe COVID-19. <i>Microorganisms</i> , 2021, 9, 2259.	3.6	14
4	Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR. <i>Scientific Reports</i> , 2019, 9, 12163.	3.3	2
5	Moving beyond unsolicited consultation: additional impact of a structured intervention on mortality in <i>Staphylococcus aureus</i> bacteraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1101-1107.	3.0	18
6	Short- versus long-course therapy in gram-negative bacilli bloodstream infections. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 851-857.	2.9	34
7	Prevalence of hepatitis E infection in HIV/HCV-coinfected patients in Spain (2012-2014). <i>Scientific Reports</i> , 2019, 9, 1143.	3.3	8
8	Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infection. <i>Mucosal Immunology</i> , 2019, 12, 232-246.	6.0	56
9	Validation of a clinical decision tree to predict if a patient has a bacteraemia due to a β -lactamase producing organism. <i>Infectious Diseases</i> , 2019, 51, 32-37.	2.8	6
10	Elevated liver stiffness is linked to increased biomarkers of inflammation and immune activation in HIV/hepatitis C virus-coinfected patients. <i>Aids</i> , 2018, 32, 1095-1105.	2.2	28
11	Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiologa Clnica</i> , 2018, 36, 268-276.	0.5	6
12	Clinical and microbiological characteristics of unusual manifestations of invasive pneumococcal disease. <i>Enfermedades Infecciosas Y Microbiologa Clnica</i> , 2018, 36, 284-289.	0.5	10
13	Dysregulation of the Immune System in HIV/HCV-Coinfected Patients According to Liver Stiffness Status. <i>Cells</i> , 2018, 7, 196.	4.1	14
14	Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3170-3175.	3.0	113
15	Impact of Low-level Viremia on Treatment Outcomes During ART - Is it Time to Revise the Definition of Virological Failure?. <i>AIDS Reviews</i> , 2018, 20, 71-72.	1.0	17
16	Acute Leg Ischaemia in an HIV-Infected Patient Receiving Antiretroviral Treatment. <i>Antiviral Therapy</i> , 2017, 22, 89-90.	1.0	10
17	Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group. <i>Enfermedades Infecciosas Y Microbiologa Clnica</i> , 2017, 35, 493-498.	0.5	3
18	Eradication of hepatitis C virus and non-liverrelated non-acquired immune deficiency syndromerelated events in human immunodeficiency virus/hepatitis C virus coinfection. <i>Hepatology</i> , 2017, 66, 344-356.	7.3	49

#	ARTICLE	IF	CITATIONS
19	Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2017, 35, 491-496.	0.3	0
20	Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2850-2856.	3.0	13
21	A Novel Single-Cell FISH-Flow Assay Identifies Effector Memory CD4 ⁺ T cells as a Major Niche for HIV-1 Transcription in HIV-Infected Patients. <i>MBio</i> , 2017, 8, .	4.1	105
22	Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2017, 35, 88-99.	0.5	12
23	Plasma mitochondrial DNA levels are inversely associated with HIV-RNA levels and directly with CD4 counts: potential role as a biomarker of HIV replication. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3159-3162.	3.0	12
24	Impact of Low-Level Viraemia on Virological Failure in HIV-1-Infected Patients with Stable Antiretroviral Treatment. <i>Antiviral Therapy</i> , 2016, 21, 345-352.	1.0	14
25	Defining the HLA class II-associated viral antigen repertoire from HIV-1-infected human cells. <i>European Journal of Immunology</i> , 2016, 46, 60-69.	2.9	57
26	Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4 ⁺ T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2016, 213, 1008-1012.	4.0	36
27	The Efficacy and Safety of Maraviroc Addition to a Stable Antiretroviral Regimen in Subjects with Suppressed Plasma HIV-RNA Is Not Influenced by Age. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 893-897.	1.1	4
28	Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 785-792.	9.1	131
29	Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015, 33, 544-556.	0.5	10
30	ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study. <i>Journal of the International AIDS Society</i> , 2014, 17, 19814.	3.0	4
31	Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1390-1396.	3.0	19
32	Darunavir and telaprevir drug interaction: total and unbound plasma concentrations in HIV/HCV-coinfected patients with cirrhosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1434-1436.	3.0	6
33	Effectiveness of Efavirenz Compared with Ritonavir-Boosted Protease-Inhibitor-Based Regimens as Initial Therapy for Patients with Plasma HIV-1 RNA above 100,000 Copies/ML. <i>Antiviral Therapy</i> , 2014, 19, 569-577.	1.0	8
34	Cirrhosis, Liver Transplantation and HIV Infection Are Risk Factors Associated with Hepatitis E Virus Infection. <i>PLoS ONE</i> , 2014, 9, e103028.	2.5	46
35	Ultrasensitive Real-Time PCR for the Clinical Management of Visceral Leishmaniasis in HIV-Infected Patients. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013, 89, 105-110.	1.4	36
36	Tropical Diseases Screening in Immigrant Patients with Human Immunodeficiency Virus Infection in Spain. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013, 88, 1196-1202.	1.4	45

#	ARTICLE	IF	CITATIONS
37	Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1453-1458.	3.0	14
38	Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2479-2486.	3.0	24
39	Changes in Body Composition and Mitochondrial Dna in HIV-1-Infected Patients Switching to Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine: A Substudy of the Bicombo Trial. <i>Antiviral Therapy</i> , 2012, 17, 711-718.	1.0	10
40	Body composition changes after switching from protease inhibitors to raltegravir. <i>Aids</i> , 2012, 26, 475-481.	2.2	62
41	Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis. <i>Journal of Infection</i> , 2012, 64, 204-211.	3.3	10
42	Invasive Pneumococcal Disease in HIV-Infected Adults. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 31-38.	2.1	17
43	Abacavir coadministration does not interfere with the suppressive activity of ribavirin in an HCV replicon system. <i>Antiviral Therapy</i> , 2011, 16, 887-893.	1.0	2
44	Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfecting patients. <i>Aids</i> , 2010, 24, 975-982.	2.2	9
45	Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2195-2203.	3.0	26
46	Response-Guided Therapy for Chronic Hepatitis C Virus Infection in Patients Coinfected with HIV: A Pilot Trial. <i>Clinical Infectious Diseases</i> , 2009, 48, 1152-1159.	5.8	22
47	Clinical significance of "anti-HBc alone" in human immunodeficiency virus-positive patients. <i>World Journal of Gastroenterology</i> , 2009, 15, 1237.	3.3	25
48	Efficacy of recombinant interleukin-2 (rIL-2) in patients with advanced HIV-1 infection and blunted immune response to HAART. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2008, 26, 27-31.	0.5	6
49	Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 793-796.	3.0	16
50	Improvements in Subcutaneous Fat, Lipid Profile, and Parameters of Mitochondrial Toxicity in Patients with Peripheral Lipoatrophy When Stavudine is Switched to Tenofovir (LIPOTEST Study). <i>HIV Clinical Trials</i> , 2008, 9, 407-417.	2.0	56
51	Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 63, 189-196.	3.0	6
52	Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 690-697.	3.0	71
53	Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients. <i>Antiviral Therapy</i> , 2007, 12, 1217-23.	1.0	4
54	Early Monitoring of Ribavirin Serum Concentration is not Useful to Optimize Hepatitis C Virus treatment in HIV-Coinfected Patients. <i>Antiviral Therapy</i> , 2007, 12, 1217-1224.	1.0	20

#	ARTICLE	IF	CITATIONS
55	Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. <i>Aids</i> , 2006, 20, 1131-1139.	2.2	45
56	Steady-State Pharmacokinetics of a Double-Boosting Regimen of Saquinavir Soft Gel plus Lopinavir plus Minidose Ritonavir in Human Immunodeficiency Virus-Infected Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4256-4262.	3.2	56
57	Tuberculous Trochanteric Bursitis: Report of 5 Cases and Literature Review. <i>Scandinavian Journal of Infectious Diseases</i> , 2004, 36, 552-558.	1.5	10
58	Pharmacokinetic Interaction Between Nevirapine and Rifampicin in HIV-Infected Patients With Tuberculosis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 28, 450-453.	2.1	120